Cardiovascular Dysfunction in Intrauterine Growth Restriction

Curr Hypertens Rep. 2022 Dec;24(12):693-708. doi: 10.1007/s11906-022-01228-y. Epub 2022 Nov 2.

Abstract

Purpose of review: We highlight important new findings on cardiovascular dysfunction in intrauterine growth restriction.

Recent findings: Intrauterine growth restriction (IUGR) is a multifactorial condition which negatively impacts neonatal growth during pregnancy and is associated with health problems during the lifespan. It affects 5-15% of all pregnancies in the USA and Europe with varying percentages in developing countries. Epidemiological studies have reported that IUGR is associated with the pathogenesis of hypertension, activation of the renin-angiotensin system (RAS), disruption in placental-mTORC and TGFβ signaling cascades, and endothelial dysfunction in IUGR fetuses, children, adolescents, and adults resulting in the development of cardiovascular diseases (CVD). Experimental studies are needed to investigate therapeutic measures to treat increased blood pressure (BP) and long-term CVD problems in people affected by IUGR. We outline the mechanisms mediating fetal programming of hypertension in developing CVD. We have reviewed findings from different experimental models focusing on recent studies that demonstrate CVD in IUGR.

Keywords: Cardiovascular disease; Hypertension; Intrauterine growth restriction; Mammalian target of rapamycin.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cardiovascular Diseases* / etiology
  • Child
  • Female
  • Fetal Growth Retardation
  • Humans
  • Hypertension*
  • Infant, Newborn
  • Placenta
  • Pregnancy
  • Renin-Angiotensin System